Agios Pharmaceuticals Gestion

Gestion contrôle des critères 3/4

Le PDG Agios Pharmaceuticals est Brian Goff, nommé en Aug2022, a un mandat de 2.25 ans. La rémunération annuelle totale est $ 3.42M, composée du salaire de 23.4% et des bonus 76.6%, y compris les actions et options de la société. détient directement 0.14% des actions de la société, d'une valeur de MX$ 89.11M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.8 ans et 7.6 ans.

Informations clés

Brian Goff

Directeur général

US$3.4m

Rémunération totale

Pourcentage du salaire du PDG	23.4%
Durée du mandat du directeur général	2.3yrs
Propriété du PDG	0.1%
Durée moyenne d'occupation des postes de direction	2.8yrs
Durée moyenne du mandat des membres du conseil d'administration	7.6yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Brian Goff a-t-elle évolué par rapport aux bénéfices de Agios Pharmaceuticals?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	US$674m
Jun 30 2024	n/a	n/a	-US$365m
Mar 31 2024	n/a	n/a	-US$353m
Dec 31 2023	US$3m	US$798k	-US$352m
Sep 30 2023	n/a	n/a	-US$220m
Jun 30 2023	n/a	n/a	-US$210m
Mar 31 2023	n/a	n/a	-US$218m
Dec 31 2022	US$12m	US$308k	-US$232m

Rémunération vs marché: La rémunération totale de Brian ($USD 3.42M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché MX ($USD 1.26M ).

Rémunération et revenus: La rémunération de Brian a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Brian Goff (55 yo)

2.3yrs

Titularisation

US$3,416,453

Compensation

Mr. Brian M. Goff, M.B.A., is Independent Director of Intellia Therapeutics, Inc. from June 2024. He is Chief Executive Officer and Director at Agios Pharmaceuticals, Inc. from August 08, 2022. He had been...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Brian Goff	CEO & Director	2.3yrs	US$3.42m	0.14% MX$ 89.1m
Cecilia Jones	Chief Financial Officer	2.2yrs	US$1.21m	0.035% MX$ 22.8m
James Burns	Corporate Secretary & Chief Legal Officer	2.8yrs	US$1.93m	0.028% MX$ 17.8m
Sarah Gheuens	Chief Medical Officer and Head of Research & Development	3.2yrs	US$2.87m	0.077% MX$ 49.5m
Tsveta Milanova	Chief Commercial Officer	1.8yrs	US$3.73m	0.023% MX$ 15.0m
Lewis Cantley	Founder	no data	US$333.51k	pas de données
Tak Mak	Founder	no data	pas de données	pas de données
Craig Thompson	Founder	no data	pas de données	pas de données
Shin-San Su	Founder	no data	pas de données	pas de données
T. Washburn	VP, Controller & Principal Accounting Officer	3.3yrs	pas de données	0.0014% MX$ 922.4k
Clive Patience	Chief Technical Operations Officer	7.4yrs	pas de données	pas de données
Christopher J. Taylor	Vice President of Investor Relations & Corporate Communications	no data	pas de données	pas de données

2.8yrs

Durée moyenne de l'emploi

55yo

Âge moyen

Gestion expérimentée: L'équipe de direction de AGIO * est considérée comme expérimentée (ancienneté moyenne 2.8 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Brian Goff	CEO & Director	2.3yrs	US$3.42m	0.14% MX$ 89.1m
Jacqualyn Fouse	Chair of the Board of Directors	6.9yrs	US$447.25k	0.25% MX$ 159.2m
Jeffrey Capello	Independent Director	1.4yrs	US$663.68k	0.0035% MX$ 2.2m
Marc Tessier-Lavigne	Member of Scientific Advisory Board	8.3yrs	US$302.85k	pas de données
Charles Sawyers	Member of Scientific Advisory Board	15.8yrs	pas de données	pas de données
Kaye Foster-Cheek	Lead Independent Director	9.9yrs	US$440.95k	0.013% MX$ 8.5m
David Schenkein	Independent Director	15.3yrs	US$417.25k	0.83% MX$ 538.5m
Joan Brugge	Member of Scientific Advisory Board	no data	pas de données	pas de données
Matthew Vander Heiden	Member of Scientific Advisory Board	16yrs	pas de données	pas de données
Scott Biller	Member of Scientific Advisory Board	3.8yrs	US$3.21m	pas de données
Cynthia Smith	Independent Director	2.3yrs	US$419.91k	0.014% MX$ 9.0m
Ralph Deberardinis	Member of Scientific Advisory Board	no data	pas de données	pas de données

7.6yrs

Durée moyenne de l'emploi

64yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de AGIO * sont considérés comme expérimentés (ancienneté moyenne 7.6 ans).

Agios Pharmaceuticals Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Agios Pharmaceuticals, Inc. Announces Board Changes

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Recent updates

Agios Pharmaceuticals, Inc. Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Agios Pharmaceuticals, Inc. Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

Agios Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

Agios Pharmaceuticals, Inc. Announces Phase 3 Energize-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Agios Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Agios Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Agios Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Agios Pharmaceuticals, Inc. Announces Board Changes

Agios Pharmaceuticals, Inc. Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Agios Pharmaceutical's PYRUKYND® Approves in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Receives Positive Chmp Opinion for Pyrukynd® (Mitapivat) for the Treatment of Pyruvate Kinase (Pk) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Agios Pharmaceuticals, Inc. Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent a- and ß-Thalassemia

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces Management Changes, Effective August 8, 2022

Insufficient new directors

Agios Presents New Clinical Data Supporting the Benefits of Pyrukynd® Treatment in Adults with PK Deficiency At European Hematology Association Annual Congress

Agios Pharmaceuticals, Inc. Announces Resignation of Bruce Car as Chief Scientific Officer, effective as of August 1, 2022

Agios Pharmaceuticals, Inc. Announces Management Changes

Agios Pharmaceuticals, Inc. Announces Executive Changes

Agios Pharmaceuticals, Inc. Announces Resignation of Ian T. Clark from the Board

Agios Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces FDA Approval of Pyrukynd (Mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Agios Pharmaceuticals, Inc. Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition

Chief Commercial Officer Darrin Miles has left the company

Insufficient new directors

Forecast to breakeven in 2021

Forecast to breakeven in 2021

Agios Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Principal Accounting Officer and VP of Accounting, Treasury & Tax Carman Alenson has left the company

Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) dropped from Russell Midcap Value Index

Agios Pharmaceuticals, Inc. Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Study of Mitapivat in Non-Transfusion-Dependent a- and ß-Thalassemia at the European Hematology Association Virtual Congress

Agios Reports Clinical Data Presentations

Agios Pharmaceuticals, Inc. Announces Closing of Oncology Business Sale to Servier

Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Agios Pharmaceuticals, Inc. Announces the Appointment of Darrin Miles to Role of Chief Commercial Officer

Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Servier Pharmaceuticals, LLC entered into a definitive agreement to acquire oncology business from Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) for $2 billion.

Agios Pharmaceuticals, Inc. Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused

Agios Pharmaceuticals, Inc. Launches Anemia ID

Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease

Third quarter 2020 earnings released: US$1.43 loss per share

Revenue misses expectations

Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia

Agios Pharmaceuticals, Inc. Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi